NHERF1 and colorectal carcinoma: By using a rational virtual screening, we herein validated RS5517 as a novel NHERF1/PDZ1 ligand that abrogates its nuclear entry exhibiting a remarkable cytotoxicity on β-catenin-depleted CRC cells which highly re-express NHERF1.